en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2021
vol. 96
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
streszczenie artykułu:
Artykuł przeglądowy

Advancement of SARS-CoV-2 infection in children

Jacek Tabarkiewicz
1
,
Paulina Frączek
2
,
Guoqian Chen
3
,
Artur Mazur
4
,
Jieming Wang
5
,
Fuyong Jiao
5

  1. Department of Human Immunology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland
  2. Student Circle of Immunology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland
  3. Xi’an Medical University, Xi’an, Shanxi, China
  4. Department of Pediatrics, Pediatric Endocrinology and Diabetes, University of Rzeszow, Rzeszow, Poland
  5. Department of Pediatrics, Shanxi Provincial People’s Hospital, Xi’an, Shanxi, China
Pediatr Pol 2021; 96 (2): 129–133
DOI: https://doi.org/10.5114/polp.2021.107396
Data publikacji online: 2021/07/01
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Novel coronavirus disease 2019 (COVID-19) is a disease characterized by respiratory symptoms caused by novel coronavirus (SARS-CoV-2). Its pathogenesis is suggested to be related with ACE2 receptors, present in various organs. Children, as a special group of patients with COVID-19, have their own unique characteristics in terms of the disease’s course. The majority of children present with asymptomatic course or have mild symptoms. In severe cases COVID-19 may manifest as a multisystem inflammatory syndrome; thus, correct identification of children at risk is particularly important in the diagnostic process. The treatment options for this disease are still based on general therapy, and related drug therapy is still at the clinical trial stage.